Belite Bio (BLTE) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Belite Bio (BLTE) has outperformed Rhythm Pharmaceuticals (RYTM) over the past year, gaining 101.7% versus a loss of 11.4%. Belite Bio is the larger company by market cap ($6.29 billion vs $6.09 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLTE | RYTM |
|---|---|---|
| Share price | $156.08 | $88.45 |
| Market cap | $6.29B | $6.09B |
| 1-day change | +0.30% | -2.56% |
| YTD return | -2.43% | -17.37% |
| 1-year return | +101.65% | -11.40% |
| 5-year return | — | +682.05% |
| Forward P/E | 69.06 | — |
| EPS (TTM) | $-2.74 | $-3.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $189.76M |
| Revenue growth (YoY) | — | +45.83% |
| Net income (latest FY) | $-77.61M | $-196.54M |
| Gross margin | — | 89.73% |
| Operating margin | — | -101.19% |
| Net margin | — | -103.57% |
| 52-week high | $200.00 | $122.20 |
| 52-week low | $76.50 | $74.50 |
| Distance from 52-week high | -21.96% | -27.62% |
| Analyst consensus | none | none |
| Avg. price target upside | +46.65% | +56.69% |
| Average volume | 182.25K | 646.31K |
| Shares outstanding | 40.27M | 68.85M |
| Employees | 41 | 414 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BLTE has outperformed RYTM by 113.1 percentage points over the past year.
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
BLTE vs RYTM FAQ
Which is bigger, Belite Bio or Rhythm Pharmaceuticals?
Belite Bio (BLTE) is larger, with a market capitalization of $6.29B compared with $6.09B for Rhythm Pharmaceuticals (RYTM).
Which stock has performed better over the past year, BLTE or RYTM?
BLTE returned +101.65% over the past 12 months, compared with -11.40% for RYTM (price return, excluding dividends). Past performance does not predict future results.
Are Belite Bio and Rhythm Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.